Weekly roundup: Innovation and deals for Optimum’s clients
SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]